Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Clinical trial NCT02073279 · COMPLETED

Trial details

NCT number: NCT02073279
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Neuromyelitis Optica (NMO)NMO Spectrum Disorder (NMOSD)

Start date: 2014-08-05
Primary completion: 2018-10-12
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.